In this episode, we speak with Alan Nafiiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.

Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.

To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments.  

Things mentioned:

• Sergii Starosyla, Co-Founder and CTO of Receptor AI.


• Semen Yesylevskyy, Co-Founder and CSO of Receptor AI. 


• Enamine, a partner to Receptor AI. 

Additional Materials: 

• SIRT1 Case Study


• BRD4 Case Study


• Selectivity Benchmark


• Platform Benchmarks and Tests


• Bifunctional Protein Degradars


• Product Deck


• End-to-End Drug Candidate Design via Active Learning

About Antiverse:

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.